Eye Care Insights

Xiidra remains highly covered by commercial (94%) and Medicare Part D (70%) plans in early 2025, supported by copay assistance—key to maintaining market position amid pending generic threats.

Phase 4 data show Miebo delivers rapid (within minutes) and sustained symptom relief over two weeks in DED.

Reproxalap NDA accepted with December 16, 2025 PDUFA date; could bring first-in-class RASP modulator to dry eye market.

Registry data show fewer complications with intraluminal sutures in PreserFlo procedures, improving postoperative safety.

ARGOS Phase IV study shows a single Durysta implant sustains IOP control and reduces medication use through 18 months, reinforcing its clinical utility for nonadherent glaucoma patients.